Renovaro Biosciences ( (RENB) ) has released a notification of late filing.
Renovaro Biosciences, filing Form 12b-25, has delayed its Form 10-Q (Quarter Report) for the period ending December 31, 2024. The primary reason for the delay is the need for additional time to finalize financial statements, particularly concerning settled equity and total outstanding equity. The company anticipates filing the report within the five-day grace period allowed by Rule 12b-25. Significant changes in financial results are expected, with notable changes in cash, insurance receivables, goodwill, and various expenses. These changes reflect forward-looking statements, still under review by the company’s auditors. Renovaro is actively working on compliance, as stated by Nathen Fuentes, the Chief Financial Officer.
More about Renovaro Biosciences
YTD Price Performance: 5.90%
Average Trading Volume: 1,199,455
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $128.4M
For a thorough assessment of RENB stock, go to TipRanks’ Stock Analysis page.